Astrana Health/$ASTH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Astrana Health
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
- Ticker
- $ASTH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,000
- Headquarters
- Alhambra, United States
- Website
- www.astranahealth.com
Astrana Health Metrics
BasicAdvanced
$1.9B
44.55
$0.82
0.90
-
Price and volume
Market cap
$1.9B
Beta
0.9
52-week high
$51.60
52-week low
$18.08
Average daily volume
323K
Financial strength
Current ratio
1.229
Quick ratio
1.19
Long term debt to equity
1.531
Total debt to equity
1.636
Dividend payout ratio (TTM)
4.57%
Interest coverage (TTM)
1.55%
Profitability
EBITDA (TTM)
174.907
Gross margin (TTM)
10.46%
Net profit margin (TTM)
1.05%
Operating margin (TTM)
2.91%
Effective tax rate (TTM)
34.73%
Revenue per employee (TTM)
$1,280,000
Management effectiveness
Return on assets (TTM)
3.76%
Return on equity (TTM)
6.90%
Valuation
Price to earnings (TTM)
44.552
Price to revenue (TTM)
0.467
Price to book
2.17
Price to tangible book (TTM)
-5.99
Price to free cash flow (TTM)
19.025
Free cash flow yield (TTM)
5.26%
Free cash flow per share (TTM)
1.92
Growth
Revenue change (TTM)
58.91%
Earnings per share change (TTM)
56.78%
3-year revenue growth (CAGR)
43.66%
3-year earnings per share growth (CAGR)
-6.12%
What the Analysts think about Astrana Health
Analyst ratings (Buy, Hold, Sell) for Astrana Health stock.
Analyst projections of the future price of Astrana Health stock.
Bulls say / Bears say
Second-quarter revenue rose 49% year on year and adjusted EBITDA rose 43%; Astrana also raised its 2026 adjusted EBITDA guidance to $255–280 million. That points to strong growth alongside improving earnings. (Astrana Health)
Astrana reported that general and administrative costs fell to 5.6% of revenue from 7.7% a year earlier, and it expects to achieve the high end of its $12–15 million Prospect integration synergies. If sustained, this operating leverage could support profit growth. (Astrana Health)
The company supports around 1.5 million patients in value-based care and is extending its Medicare Advantage footprint, including new Hawaii and Texas agreements. The Texas agreement adds about 3,000 professional-risk lives, giving Astrana further scope to grow its platform. (Astrana Health)
Astrana disclosed a cybersecurity incident at its management subsidiary and said it could not yet estimate the full impact, including response costs, legal or regulatory matters, and possible effects on patients and its reputation. The eventual costs and operational fallout remain uncertain. (Astrana Health)
A short seller has alleged that Astrana relies on subjective accounting estimates and raised concerns about its $545 million related-party loan; these remain allegations, not established findings. A law firm announced an investor-securities investigation, adding governance and litigation uncertainty. (Investing.com, GlobeNewswire)
Care Partners, Astrana’s largest segment, grew revenue 48% in the second quarter, but its operating income fell 14%. That mismatch raises the risk that rapid growth in the core business may not translate into stronger segment profits. (TradingKey)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2026.
Astrana Health Financial Performance
Revenues and expenses
Astrana Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Astrana Health News
AllArticlesVideos
Funds containing Astrana Health
Fund name | Fund size | $ASTH weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.14% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.14% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.14% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.09% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.